Last reviewed · How we verify

Thymosin-α1 — Competitive Intelligence Brief

Thymosin-α1 (Thymosin-α1) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory peptide. Area: Immunology / Oncology.

phase 3 Immunomodulatory peptide Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Thymosin-α1 (Thymosin-α1) — Sun Yat-sen University. Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thymosin-α1 TARGET Thymosin-α1 Sun Yat-sen University phase 3 Immunomodulatory peptide
IM862 IM862 Cytran phase 3 Immunomodulatory peptide IL-2 pathway / T-cell activation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory peptide class)

  1. Cytran · 1 drug in this class
  2. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thymosin-α1 — Competitive Intelligence Brief. https://druglandscape.com/ci/thymosin-1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: